Citigroup’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-29,700
Closed -$935K 5810
2022
Q2
$935K Buy
+29,700
New +$1.04M ﹤0.01% 2716
2021
Q4
Sell
-74,900
Closed -$5.6M 5808
2021
Q3
$5.6M Buy
74,900
+29,800
+66% +$2.5M ﹤0.01% 1744
2021
Q2
$4.17M Buy
45,100
+42,300
+1,511% +$3.6M ﹤0.01% 2055
2021
Q1
$248K Buy
+2,800
New +$278K ﹤0.01% 3899

Other funds holding ARKG

Citigroup's ARKG Position: Q1 2026 in Review

Citigroup reduced its ARK Genomic Revolution ETF (ARKG) stake by 33% in Q1 2026, selling an estimated $27.3M and leaving 1,899,044 shares worth $50.2M. The position accounts for 0.02% of the portfolio, ranked #643.

Citigroup first reported a position in ARKG in Q1 2018 and has held it in 33 quarters since. The position peaked at $82M in Q4 2025. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

  • Citigroup held 1,899,044 shares of ARK Genomic Revolution ETF worth $50.2M as of Q1 2026.
  • Citigroup sold 931,940 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $27.3M.
  • ARK Genomic Revolution ETF made up 0.02% of Citigroup's portfolio in Q1 2026, its #643 holding.
  • Citigroup first reported a position in ARK Genomic Revolution ETF in Q1 2018 and has held it in 33 quarters since.
  • Citigroup's ARK Genomic Revolution ETF position peaked at $82M in Q4 2025.
  • 218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.